Pfizer-birthed Ziarco raises $33m for skin drugs
This article was originally published in Scrip
Executive Summary
A company formed by Pfizer's former head of allergy and respiratory research in Sandwich, UK, has raised $33.1m in a series B round to fund development of novel candidates to treat atopic dermatitis and psoriasis. Ziarco, headed by Mike Yeadon, will use the funds to complete proof of concept Phase II trials of its two lead candidates.
You may also be interested in...
Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics
UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.